Conquering Resistance in HER2-Targeted Breast Cancer Therapies
Received Date: Jun 01, 2024 / Published Date: Jun 27, 2024
Abstract
HER2-positive breast cancer represents a subtype characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), which drives aggressive tumor growth and poorer prognosis. Targeted therapies such as HER2-directed monoclonal antibodies (trastuzumab, pertuzumab) and tyrosine kinase inhibitors (lapatinib,neratinib) have transformed treatment outcomes. However, resistance mechanisms often limit their long-term efficacy. This review explores current understanding of resistance mechanisms in HER2-targeted therapies, including HER2 alterations, downstream signaling pathways, and immune evasion strategies. Emerging strategies to overcome resistance, such as combination therapies, novel HER2-targeted agents, and immune checkpoint inhibitors, are discussed. Advances in biomarker development and personalized medicine approaches are also highlighted to optimize treatment selection and improve outcomes for HER2-positive breast cancer patients
Citation: Maegen S (2024) Conquering Resistance in HER2-Targeted BreastCancer Therapies. Breast Can Curr Res 9: 258.
Copyright: © 2024 Maegen S. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
黑料网 Journals
Article Usage
- Total views: 98
- [From(publication date): 0-2024 - Nov 25, 2024]
- Breakdown by view type
- HTML page views: 70
- PDF downloads: 28
